An evaluation of the safety, tolerability, and pharmacodynamic effects of GSK189075 [remogliflozin etabonate] when administered with furosemide or hydrochlorothiazide.
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2012
At a glance
- Drugs Furosemide; Hydrochlorothiazide; Remogliflozin etabonate
- Indications Heart failure; Hypertension; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
- 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 May 2008 New trial record.